SCHEMBL7065220

SCHEMBL7065220

CCOC(C)O[C@H]1C(=O)N(C(=O)OC(C)(C)C)[C@H]1c1ccsc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 9/20 0.37
ALDH1A1 P00352 3/20 0.34
POLB P06746 2/20 0.34
KDM4E B2RXH2 2/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
GAA P10253 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NR1I2 O75469 4/20 0.34
KLK7 P49862 2/20 0.33
KLK5 Q9Y337 1/20 0.33
MCL1 Q07820 1/20 0.33
GPR119 Q8TDV5 1/20 0.31
SIRT3 Q9NTG7 1/20 0.31
SIRT5 Q9NXA8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7662051 1.00 ADORA2B (0.37) ADORA2BALDH1A1POLBKDM4EHPGD
SCHEMBL3784269 0.85 ELANE (0.43) KLK7KLK5GPR119
SCHEMBL28379112 0.85 ELANE (0.43) KLK7KLK5GPR119
SCHEMBL9286553 0.85 ELANE (0.43) KLK7KLK5GPR119
SCHEMBL6860067 0.80 ADORA2B (0.39) ADORA2BALDH1A1POLBKDM4EHPGD
SCHEMBL6860058 0.80 ADORA2B (0.39) ADORA2BALDH1A1POLBKDM4EHPGD
SCHEMBL6860063 0.80 ADORA2B (0.39) ADORA2BALDH1A1POLBKDM4EHPGD
SCHEMBL5963831 0.74 KLK7 (0.33) KLK7KLK5
SCHEMBL7729786 0.74 ELANE (0.47) ALDH1A1POLBKDM4EHPGDGAA
SCHEMBL8593171 0.73 ADORA2B (0.45) ADORA2BALDH1A1POLBKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030083497-A1 Taxoids, their preparation and pharmaceutical compositions containing them AVENTIS PHARMA, S.A. 2003-05-01 US disclosed
US-6384071-B2 ANTITUMOR AGENTS AVENTIS PHARMA, S.A. (FR) 2002-05-07 US disclosed
US-20010021783-A1 New taxoids, their preparation and pharmaceutical compositions containing them Rhône-Poulenc Rorer S.A. 2001-09-13 US disclosed
US-6194582-B1 MULTI-DRUG RESISTANCE RHONE-POULENC RORER S.A. (FR) 2001-02-27 US disclosed
US-5814658-A Taxoids, their preparation and pharmaceutical compositions containing them RHONE-POULENC RORER S.A. (FR) 1998-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083497-A1 Taxoids, their preparation and pharmaceutical compositions containing them TBXA2R, CBR1, CBR3 ADORA2B 1044/4885ALDH1A1 665/4885POLB 1184/4885
US-20010021783-A1 New taxoids, their preparation and pharmaceutical compositions containing them CBR1, TBXA2R, CBR3 ADORA2B 929/4885ALDH1A1 640/4885POLB 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.